Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50M
QNRX sits 92% above its 52-week low of $3.25 on light trading volume (0.1× avg).
Summary
Quoin Pharmaceuticals announced a private placement financing of up to $50 million. The company has a market cap of approximately $10.4 million, so this financing is highly dilutive and could significantly increase the share count. The terms include 6,305,300 ADSs at $4.88 with warrants for 3,152,650 ADSs at $6.10, providing $30.8 million upfront and up to $19.2 million from warrant exercise. Insiders bought 57,370 ADSs for approximately $280,000, and closing is expected August 31, 2026. This follows positive interim data from the Phase 2/3 study of QRX003 in Netherton Syndrome reported earlier today, which may have provided a favorable backdrop for the raise. The financing addresses the going concern doubt reiterated in the Q2 10-Q filed on August 14, 2026.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The 8-K details terms: 6,305,300 ADSs at $4.88 with warrants for 3,152,650 ADSs at $6.10; $30.8M upfront, up to $19.2M from warrant exercise; insiders bought 57,370 ADSs for ~$280K; closing expected Aug. 31, 2026.
At the time of this announcement, QNRX was trading at $6.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.4M. The 52-week trading range was $3.25 to $41.80. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.